This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
NRx Pharmaceuticals (NRXP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?
by Kanishka Das
NRXP is expected to provide updates on its pipeline candidates being developed for treating central nervous system disorders when it reports fourth-quarter earnings release.
Best Momentum Stocks to Buy for January 6th
by Zacks Equity Research
NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.
New Strong Buy Stocks for January 6th
by Zacks Equity Research
ALK, AHT, NRXP, PDEX and EGAN have been added to the Zacks Rank #1 (Strong Buy) List on January 6, 2024.
Best Momentum Stocks to Buy for December 30th
by Zacks Equity Research
CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.
New Strong Buy Stocks for December 30th
by Zacks Equity Research
CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024.
New Strong Buy Stocks for December 26th
by Zacks Equity Research
EGAN,ACMR, AVO, BB and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 26, 2024.
New Strong Buy Stocks for December 24th
by Zacks Equity Research
FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024.
NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why
by Zacks Equity Research
NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
The latest trading day saw NRx Pharmaceuticals, Inc. (NRXP) settling at $3.14, representing a +0.64% change from its previous close.
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, NRx Pharmaceuticals, Inc. (NRXP) closed at $3.04, indicating a +0.66% shift from the previous trading day.
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
NRx Pharmaceuticals (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for April 4th
by Zacks Equity Research
DELL, NRXP, STEP, TCOM and PARAA have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.
Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree
by Sweta Killa
We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.
NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up
by Zacks Equity Research
NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.
All You Need to Know About NRx Pharmaceuticals, Inc. (NRXP) Rating Upgrade to Buy
by Zacks Equity Research
NRx Pharmaceuticals, Inc. (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Company News for Dec 30, 2021
by Zacks Equity Research
Companies in The News Are: FCEL,CALM,NRXP,AAPL
Company News for Nov 30, 2021
by Zacks Equity Research
Companies in the news are: KRYS, ADGI, NRXP, HTZ
IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals
by Zacks Equity Research
IQVIA (IQV) and NRx are set to work closely to support activities essential for emergency use authorization of ZYESAMI.